Content area

Abstract

Summary

Most patients with Alzheimer's disease present with amnestic problems; however, a substantial proportion, over-represented in young-onset cases, have atypical phenotypes including predominant visual, language, executive, behavioural, or motor dysfunction. In the past, these individuals often received a late diagnosis; however, availability of CSF and PET biomarkers of Alzheimer's disease pathologies and incorporation of atypical forms of Alzheimer's disease into new diagnostic criteria increasingly allows them to be more confidently diagnosed early in their illness. This early diagnosis in turn allows patients to be offered tailored information, appropriate care and support, and individualised treatment plans. These advances will provide improved access to clinical trials, which often exclude atypical phenotypes. Research into atypical Alzheimer's disease has revealed previously unrecognised neuropathological heterogeneity across the Alzheimer's disease spectrum. Neuroimaging, genetic, biomarker, and basic science studies are providing key insights into the factors that might drive selective vulnerability of differing brain networks, with potential mechanistic implications for understanding typical late-onset Alzheimer's disease.

Details

Title
New insights into atypical Alzheimer's disease in the era of biomarkers
Author
Graff-Radford, Jonathan 1 ; Keir X X Yong 2 ; Apostolova, Liana G 3 ; Bouwman, Femke H 4 ; Carrillo, Maria 5 ; Dickerson, Bradford C 6 ; Rabinovici, Gil D 7 ; Schott, Jonathan M 2 ; Jones, David T 8 ; Murray, Melissa E 9 

 Department of Neurology, Mayo Clinic, Rochester, MN, USA 
 Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK 
 Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA 
 Alzheimer Center Amsterdam, Department of Neurology, Amsterdam University Medical Center, Amsterdam, Netherlands 
 Alzheimer's Association, Chicago, IL, USA 
 Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA 
 Department of Neurology, Radiology, and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA 
 Department of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Radiology, Mayo Clinic, Rochester, MN, USA 
 Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA 
Pages
222-234
Section
Review
Publication year
2021
Publication date
Mar 2021
Publisher
Elsevier Limited
ISSN
14744422
e-ISSN
14744465
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2490538759
Copyright
©2021. Elsevier Ltd